Evidence map›Paper›PMID 34289836›Full record

ArticleBMC medicine2021

Variability of multi-omics profiles in a population-based child cohort.

Marta Gallego-Paüls, Carles Hernández-Ferrer, Mariona Bustamante, Xavier Basagaña, Jose Barrera-Gómez, Chung-Ho E Lau, Alexandros P Siskos, Marta Vives-Usano, Carlos Ruiz-Arenas, John Wright and 15 more

Open access · goldAbstract read
In one paragraph

Article in BMC medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Relevance and challenges of exposome studies for environmental health research.Environmental health : a global access science source · 2026
    Review
  4. Article
  5. Article
  6. Illuminating diabetesWorld journal of diabetes · 2025
    Review
  7. Review
  8. From Lab to Clinic: Success Stories of Repurposed Drugs in Treating Major Diseases.Advances in pharmacological and pharmaceutical sciences · 2025
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 11 institutions in 5 countries.

Marta Gallego-PaülsISGlobal, Barcelona, Spain.
Carles Hernández-FerrerISGlobal, Barcelona, Spain.
Mariona BustamanteISGlobal, Barcelona, Spain.
Xavier BasagañaISGlobal, Barcelona, Spain.
Jose Barrera-GómezISGlobal, Barcelona, Spain.
Chung-Ho E LauMRC Centre for Environment and Health, School of Public Health, Imperial College London, London, UK.
Alexandros P SiskosCancer Metabolism & Systems Toxicology Group, Division of Cancer, Department of Surgery & Cancer and Division of Systems Medicine, Department of Metabolism, Digestion & Reproduction, Imperial College London, London, UK.
Marta Vives-UsanoISGlobal, Barcelona, Spain.
Carlos Ruiz-ArenasISGlobal, Barcelona, Spain.
John WrightBradford Institute for Health Research, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK.
Remy SlamaTeam of Environmental Epidemiology applied to Reproduction and Respiratory Health, Institute for Advanced Biosciences (IAB), Inserm, CNRS, Université Grenoble Alpes, Grenoble, France.
Barbara HeudeUniversité de Paris, Centre for Research in Epidemiology and Statistics (CRESS), INSERM, INRAE, F-75004, Paris, France.
Maribel CasasISGlobal, Barcelona, Spain.
Regina GrazulevicieneDepartment of Environmental Sciences, Vytautas Magnus University, Kaunas, Lithuania.
Leda ChatziDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Eva BorràsUniversitat Pompeu Fabra (UPF), Barcelona, Spain.
Eduard SabidóUniversitat Pompeu Fabra (UPF), Barcelona, Spain.
Ángel CarracedoMedicine Genomics Group, Centro de Investigación Biomédica en Red Enfermedades Raras (CIBERER), University of Santiago de Compostela, CEGEN-PRB3, Santiago de Compostela, Spain.
Xavier EstivillCenter for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
Jose UrquizaISGlobal, Barcelona, Spain.
Muireann CoenDivision of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, South Kensington, London, UK.
Hector C KeunCancer Metabolism & Systems Toxicology Group, Division of Cancer, Department of Surgery & Cancer and Division of Systems Medicine, Department of Metabolism, Digestion & Reproduction, Imperial College London, London, UK.
Juan R GonzálezISGlobal, Barcelona, Spain.
Martine VrijheidISGlobal, Barcelona, Spain.
Léa MaitreISGlobal, Barcelona, Spain. lea.maitre@isglobal.org.ORCID 0000-0003-3682-7117
Universitat Pompeu Fabra · ESImperial College London · GBAstraZeneca (United Kingdom) · GBBradford Teaching Hospitals NHS Foundation Trust · GBCentre for Genomic Regulation · ESCentre National de la Recherche Scientifique · FRInserm · FRMRC Centre for Environment and HealthUniversidade de Santiago de Compostela · ESUniversity of Southern California · USVytautas Magnus University · LT

Funding

Medical Research Council MR/N024397/1
6 · The paper itself

Abstract

backgroundMultiple omics technologies are increasingly applied to detect early, subtle molecular responses to environmental stressors for future disease risk prevention. However, there is an urgent need for further evaluation of stability and variability of omics profiles in healthy individuals, especially during childhood.

methodsWe aimed to estimate intra-, inter-individual and cohort variability of multi-omics profiles (blood DNA methylation, gene expression, miRNA, proteins and serum and urine metabolites) measured 6 months apart in 156 healthy children from five European countries. We further performed a multi-omics network analysis to establish clusters of co-varying omics features and assessed the contribution of key variables (including biological traits and sample collection parameters) to omics variability.

resultsAll omics displayed a large range of intra- and inter-individual variability depending on each omics feature, although all presented a highest median intra-individual variability. DNA methylation was the most stable profile (median 37.6% inter-individual variability) while gene expression was the least stable (6.6%). Among the least stable features, we identified 1% cross-omics co-variation between CpGs and metabolites (e.g. glucose and CpGs related to obesity and type 2 diabetes). Explanatory variables, including age and body mass index (BMI), explained up to 9% of serum metabolite variability.

conclusionsMethylation and targeted serum metabolomics are the most reliable omics to implement in single time-point measurements in large cross-sectional studies. In the case of metabolomics, sample collection and individual traits (e.g. BMI) are important parameters to control for improved comparability, at the study design or analysis stage. This study will be valuable for the design and interpretation of epidemiological studies that aim to link omics signatures to disease, environmental exposures, or both.

Indexed as

Diabetes Mellitus, Type 2MicroRNAsChildCohort StudiesCross-Sectional StudiesDNA MethylationHumansMicroRNAsChildrenCross-omicsDNA methylationExposomeMetabolomicsmiRNAmRNAMulti-omicsPopulation studyVariability

Identifiers

PMID34289836
PMCPMC8296694
OpenAlexW3184567430

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.